Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 323 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adenocarcinoma of the Prostate Stage II Clear all
Completed Phase 3 Interventional

Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00062309
View directory record Official record
Conditions
Prostate Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 9, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy

NCT00888654
View directory record Official record
Conditions
Prostate Cancer
Interventions
B-Dim, Radical Prosatectomy
Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 9, 2026, 1:41 AM EDT
Active, not recruiting Phase 3 Interventional

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

NCT03367702
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma AJCC v7
Interventions
Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
276
States / cities
Mobile, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 230 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 9, 2026, 1:41 AM EDT
Terminated Phase 2 Interventional

Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer

NCT00040170
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
MVA-MUC1-IL2
Biological
Lead sponsor
Transgene
Industry
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
3
States / cities
Tucson, Arizona • Los Angeles, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2006 · Synced Oct 9, 2026, 1:41 AM EDT
Active, not recruiting No phase listed Observational

Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer

NCT01352429
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Proton Therapy, IMRT
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 9, 2026, 1:41 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis

NCT04252625
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Q-Urol, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 9, 2026, 1:41 AM EDT
Completed Not applicable Interventional

Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer

NCT01117935
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
intensity modulated external beam radiation therapy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 9, 2026, 1:41 AM EDT
Terminated Phase 2 Interventional Results available

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

NCT03570476
View directory record Official record
Conditions
Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Olaparib, Radical Prostatectomy
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 9, 2026, 1:41 AM EDT
Completed Phase 2 Interventional

Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

NCT00087035
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, erlotinib hydrochloride
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
65 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
3
States / cities
Los Angeles, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 9, 2026, 1:41 AM EDT
Completed Phase 1Phase 2 Interventional

Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma

NCT00252941
View directory record Official record
Conditions
Prostate Cancer, Post-Brachytherapy Bladder Outlet Obstruction
Interventions
Memokath 028SW Urethral Stent
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2010 · Synced Oct 9, 2026, 1:41 AM EDT
Not listed Phase 2 Interventional

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

NCT00003717
View directory record Official record
Conditions
Prostate Cancer
Interventions
estramustine phosphate sodium, paclitaxel
Drug
Lead sponsor
St. Barnabas Medical Center
Other
Eligibility
Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
Livingston, New Jersey • Long Branch, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 9, 2026, 1:41 AM EDT
Terminated Phase 1Phase 2 Interventional

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

NCT02805894
View directory record Official record
Conditions
Prostate Cancer
Interventions
NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT
Drug
Lead sponsor
Nanobiotix
Industry
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 9, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

NCT03113617
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma
Interventions
Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Andrei Iagaru
Other
Eligibility
19 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 9, 2026, 1:41 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005960
View directory record Official record
Conditions
Pain, Prostate Cancer
Interventions
filgrastim, cyclophosphamide, docetaxel, doxorubicin hydrochloride, pain therapy
Biological · Drug · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Los Angeles, California • Vero Beach, Florida • Great Neck, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 9, 2026, 1:41 AM EDT
Terminated Phase 2 Interventional

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

NCT00004026
View directory record Official record
Conditions
Prostate Cancer
Interventions
CT-2584, chemotherapy
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 9, 2026, 1:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

NCT05113537
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Metastatic Castration-resistant Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions
Abemaciclib, Lutetium Lu 177-PSMA-617
Drug
Lead sponsor
Vadim S Koshkin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 9, 2026, 1:41 AM EDT
Not listed Phase 1Phase 2 Interventional

Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer

NCT00003183
View directory record Official record
Conditions
Prostate Cancer
Interventions
filgrastim, mitoxantrone hydrochloride
Biological · Drug
Lead sponsor
Hope Cancer Institute, Inc.
Industry
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 9, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00049257
View directory record Official record
Conditions
Prostate Cancer
Interventions
carboplatin, paclitaxel
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 9, 2026, 1:41 AM EDT
Completed Phase 2Phase 3 Interventional Results available

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

NCT02678351
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Interventions
68Ga-PSMA-11, Magnetic resonance imaging (MRI), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 9, 2026, 1:41 AM EDT
Completed Phase 2 Interventional

Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

NCT00006359
View directory record Official record
Conditions
Prostate Cancer
Interventions
LHRH agonist, antiandrogen, radiation therapy, Brachytherapy boost
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
26
States / cities
Lewes, Delaware • Newark, Delaware • Wilmington, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 9, 2026, 1:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

NCT04019327
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
Interventions
Talazoparib, Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 9, 2026, 1:41 AM EDT
Completed Phase 2 Interventional

Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer

NCT00002889
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, goserelin, leuprolide acetate, low-LET photon therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
30 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 9, 2026, 1:41 AM EDT
Completed Phase 2 Interventional

Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

NCT00151060
View directory record Official record
Conditions
Prostate Cancer
Interventions
Estramustine, Etoposide, Paclitaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 9, 2026, 1:41 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT01368588
View directory record Official record
Conditions
Prostate Cancer
Interventions
three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
454
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 9, 2026, 1:41 AM EDT